Yale AHA/Bugher Center of Research Excellence in Hemorrhagic Stroke Prevention & Treatment
Description: The Yale AHA Bugher Center of Excellence in Hemorrhagic Stroke Research will bring together multidisciplinary scientists, physicians and trainees to find new ways to prevent and treat intracerebral hemorrhage (ICH). ICH is the most devastating form of stroke with very high rates of death and disability in survivors. The most common risk factor for an ICH is hypertension. Hypertension leads to both poor outcomes after an initial ICH and increases the risk of recurrence. This burden is particularly high in racial and ethnic minorities. Attacking this problem is a central theme in our Center. Project 1 focuses on the treatment of hypertension in acute ICH. Dysregulation of sympathetic and renin-angiotensin system pathways can cause hypertension and impact inflammatory responses, highlighting the importance of these pathways in the management of acute ICH. Using both in vitro and in vivo approaches, this project will test different antihypertensive medications on the acute inflammatory cascade and neurological recovery in experimental ICH in multiple models of chronic hypertension. Project 2 focuses on ICH survivors who have ongoing hypertension, a group particularly vulnerable to recurrent ICH, thrombosis and dementia. The project will examine the effectiveness of aldosterone inhibition in achieving blood pressure control in racially and ethnically diverse patients and include studies of neurohumoral biomarkers that may inform blood pressure medication selection. Included in this project is a nested safety and feasibility study of renal denervation, which may allow for better blood pressure control. Project 3 focuses on genomics at the population level. Large data sets will be analyzed to develop genetic risk scores that associate with resistant hypertension and recurrent ICH in survivors. In patients who have both ICH and atrial fibrillation, a risk factor for stroke that generally requires anticoagulation, whether this risk score impacts the benefit versus risk of anticoagulation will be determined. The risk scores will be used to develop a personalized medicine tool to deliver the genetic risk information to treating providers to aid in decision-making. Together the Center will advance the treatment of hypertension in ICH patients, inspire high quality research in our trainees and enhance collaborations with Quinnipiac University and other Network partners, all to reduce the burden of hemorrhagic stroke.
Funder: American Heart Association
Amount: $677,000
Funding type: research
Funder scheme: Bugher Foundation Stroke Center
Start date: 2021-01-01
End date: 2024-12-31
Investigator: Lauren Sansing (lead)
Institution: Yale University
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: 814669
OpenAlex ID: G4668613766
